| Dr Paola Andrea D'aleman Poveda, MD | |
|
1219 Sw 4th Ave Unit 1, Ontario, OR 97914-4500 | |
| (541) 889-2668 | |
| Not Available |
| Full Name | Dr Paola Andrea D'aleman Poveda |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1219 Sw 4th Ave Unit 1, Ontario, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295206589 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 190820 (Oregon) | Primary |
| Entity Name | Valley Family Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295415032 PECOS PAC ID: 0547169591 Enrollment ID: O20040305000532 |
News Archive
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
An international team led by St. Jude Children's Research Hospital scientists finds unique combinations of cells and mutations lie at the heart of cancer subgroup revealed for the first time in a pediatric brain tumor
Shengtai Pharmaceutical, Inc. announced today that Weifang Shengtai Pharmaceutical, the Company's subsidiary in Changle, Shandong, China ("the Shandong Subsidiary"), held an unveiling ceremony for the "Joint University-Business Community Program" between the Company's Shandong subsidiary and the Hubei University of Technology ("HUT") in Changle, Shandong, China on December 4, 2010.
A new Boston University School of Medicine (BUSM) study has found that low-income and minority parents/guardians were receptive toward vaccinating boys against Human Papilloma Virus (HPV). However, racial/ethnic differences emerged in attitudes regarding school-entry mandates. The findings appear online in the journal Clinical Pediatrics.
A recent review published in the journal Global Challenges in October 2020, sums up what is currently known about the treatment of COVID-19 during pregnancy and offers recommendations for how healthcare professions might better manage pregnant COVID-19 patients in the future.
› Verified 3 days ago
| Entity Name | Saint Alphonsus Medical Center- Ontario Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093034159 PECOS PAC ID: 1456488899 Enrollment ID: O20100713000593 |
News Archive
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
An international team led by St. Jude Children's Research Hospital scientists finds unique combinations of cells and mutations lie at the heart of cancer subgroup revealed for the first time in a pediatric brain tumor
Shengtai Pharmaceutical, Inc. announced today that Weifang Shengtai Pharmaceutical, the Company's subsidiary in Changle, Shandong, China ("the Shandong Subsidiary"), held an unveiling ceremony for the "Joint University-Business Community Program" between the Company's Shandong subsidiary and the Hubei University of Technology ("HUT") in Changle, Shandong, China on December 4, 2010.
A new Boston University School of Medicine (BUSM) study has found that low-income and minority parents/guardians were receptive toward vaccinating boys against Human Papilloma Virus (HPV). However, racial/ethnic differences emerged in attitudes regarding school-entry mandates. The findings appear online in the journal Clinical Pediatrics.
A recent review published in the journal Global Challenges in October 2020, sums up what is currently known about the treatment of COVID-19 during pregnancy and offers recommendations for how healthcare professions might better manage pregnant COVID-19 patients in the future.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paola Andrea D'aleman Poveda, MD 46 Fritholme Gardens, Paget, PAGET PG 04 Ph: () - | Dr Paola Andrea D'aleman Poveda, MD 1219 Sw 4th Ave Unit 1, Ontario, OR 97914-4500 Ph: (541) 889-2668 |
News Archive
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
An international team led by St. Jude Children's Research Hospital scientists finds unique combinations of cells and mutations lie at the heart of cancer subgroup revealed for the first time in a pediatric brain tumor
Shengtai Pharmaceutical, Inc. announced today that Weifang Shengtai Pharmaceutical, the Company's subsidiary in Changle, Shandong, China ("the Shandong Subsidiary"), held an unveiling ceremony for the "Joint University-Business Community Program" between the Company's Shandong subsidiary and the Hubei University of Technology ("HUT") in Changle, Shandong, China on December 4, 2010.
A new Boston University School of Medicine (BUSM) study has found that low-income and minority parents/guardians were receptive toward vaccinating boys against Human Papilloma Virus (HPV). However, racial/ethnic differences emerged in attitudes regarding school-entry mandates. The findings appear online in the journal Clinical Pediatrics.
A recent review published in the journal Global Challenges in October 2020, sums up what is currently known about the treatment of COVID-19 during pregnancy and offers recommendations for how healthcare professions might better manage pregnant COVID-19 patients in the future.
› Verified 3 days ago
Stephen K Ames, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 840 Sw 4th Avenue, Suite 105, Ontario, OR 97914 Phone: 541-881-2380 Fax: 541-881-2389 | |
Nora Francisco De La Paz, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 932 W Idaho Ave Ste 101, Ontario, OR 97914 Phone: 541-889-6476 Fax: 541-889-7403 | |
Mrs. Sandra Dunbrasky, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1219 Sw 4th Ave, Suite 1, Ontario, OR 97914 Phone: 541-889-2668 Fax: 541-889-2997 | |
Kevin Francis Wade, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1219 Sw 4th Ave, Ontario, OR 97914 Phone: 541-889-2668 Fax: 541-889-2997 | |
Dr. Thomas Kent Geraci, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1219 Sw 4th Ave, Suite 1, Ontario, OR 97914 Phone: 541-889-2668 |